Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07146230 · ClinicalTrials.gov registry record · Phase 2
The Selective Personalized Radio-Immunotherapy for Locally Advanced Non-Small Cell Lung Cancer Trial 2
A Phase 2 study, sponsored by Montefiore Medical Center.
- Not yet
- Registry status
- Phase 2
- Development phase
- 52
- Enrollment target
NCT07146230: Clinical Trial Phase 2 study, sponsored by Montefiore Medical Center.
NCT07146230 is a Phase 2 study that has not yet begun recruiting, run by Montefiore Medical Center. The registered enrollment target is 52 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (61% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07146230, a Phase 2 study, has not yet begun recruiting, sponsored by Montefiore Medical Center.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 52 participants
- Enrollment target
Study Summary
This is a randomized trial evaluating the efficacy and safety of sequential dual-agent immunotherapy and risk-adapted radiotherapy for patients with locally advanced non-small cell lung cancer (NSCLC) with a PD-L1 tumor proportion score of at least 50%. Participants will be randomized between two dual-agent immunotherapy regimens: durvalumab + monalizumab versus durvalumab + oleclumab.
Primary Outcome
Response rate will be assessed using Positron Emission Tomography Response Criteria in Solid Tumors (PERCIST) criteria prior to radiotherapy initiation. Response rate will be defined as a ≥ 30% decline in maximum standardized uptake value (SUV) without development of new disease sites. Response rates, which include partial metabolic responses and complete metabolic responses, will be presented as a count and percentage for each study arm. Participants who do not undergo FDG-PET after completion
Interventions
- RADIATION Radiotherapy
- DRUG Durvalumab
- DRUG Monalizumab
- DRUG Oleclumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2026-09 |
| Est. Completion | 2029-02 |
| Phase | Phase 2 |
What is known before NCT07146230 opens enrollment
NCT07146230 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 52 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (61% lower).
The record links to 0 conditions, and to 4 interventions - of which Radiotherapy is the first listed.
NCT07146230 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07146230 about?
NCT07146230 is a clinical study titled "The Selective Personalized Radio-Immunotherapy for Locally Advanced Non-Small Cell Lung Cancer Trial 2". This is a randomized trial evaluating the efficacy and safety of sequential dual-agent immunotherapy and risk-adapted radiotherapy for patients with locally advanced non-small cell lung cancer (NSCLC) with a PD-L1 tumor proportion score of at least 50%. Participants will be randomized between two du...
What is the current status of trial NCT07146230?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 52 participants. The study started on 2026-09. Estimated completion is 2029-02.
What interventions are being tested in trial NCT07146230?
The interventions under investigation include: Radiotherapy (RADIATION), Durvalumab (DRUG), Monalizumab (DRUG), Oleclumab (DRUG).
Who is sponsoring clinical trial NCT07146230?
This trial is sponsored by Montefiore Medical Center, which has 345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07146230's enrollment target sits among peer trials
52 1181st of 2000 higher than 811 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02630121 · 52 participants · Phase 4
Effect of Oxymetazoline Hydrochloride in Combination With Fluticasone Propionate on the Apnea Hypopnea Index (AHI) in Subject With Persistent Nasal Congestion and Mild Obstructive Sleep Apnea
- NCT03629171 · 52 participants · Phase 2
Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia
- NCT04128748 · 52 participants · Phase 1
Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
- NCT04150497 · 52 participants · Phase 1
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia